BPC-157 + TB-500 Stack vs Vasoactive Intestinal Peptide (VIP)
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
BPC-157 + TB-500 Stack
The most widely researched peptide stack for tissue repair, combining BPC-157 (angiogenesis and growth factor upregulation) with TB-500 (actin regulation and cell migration). The two compounds address complementary and non-overlapping stages of the healing cascade, producing synergistic effects in tendon, ligament, muscle, and gut injury research models.
Full profileVasoactive Intestinal Peptide (VIP)
28-amino acid neuropeptide found throughout the CNS, gut, and immune system. Functions as a potent anti-inflammatory, vasodilator, and neurotrophic factor. Research applications include CIRS (Chronic Inflammatory Response Syndrome), pulmonary arterial hypertension, autoimmune conditions, and gut motility disorders. Intranasal administration is most studied for CIRS and neuroinflammatory conditions.
Full profile| BPC-157 + TB-500 Stack | Vasoactive Intestinal Peptide (VIP) | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Wolverine Stack, BPC TB500 combination, healing stack, BPC-157 TB-500 | VIP, vasoactive intestinal polypeptide, PHM-27 |
| Evidence | Research-stage | Investigational (in trials) |
| Dosing range | BPC-157 250mcg + TB-500 2.5mg–BPC-157 750mcg + TB-500 7.5mg varies by component, 2–3x per week | 25mcg–100mcg mcg, Daily intranasal or 1–2x weekly subcutaneous |
| Administration | Subcutaneous injection, Intramuscular injection | Intranasal spray, Subcutaneous injection, Inhalation (nebulized) |
| Key side effects | BPC-157: nausea (rare), dizziness, lightheadedness, TB-500: fatigue, headache, injection site reactions, No documented combination-specific adverse effects, Theoretical oncological considerations (angiogenesis stimulation) — relevant in cancer history | Facial flushing, Transient hypotension, Nasal irritation (intranasal route), Tachycardia |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: BPC-157 + TB-500 Stack is research-stage, while Vasoactive Intestinal Peptide (VIP) is investigational (in trials).
- Administration: BPC-157 + TB-500 Stack — Subcutaneous injection, Intramuscular injection; Vasoactive Intestinal Peptide (VIP) — Intranasal spray, Subcutaneous injection, Inhalation (nebulized).
- Dosing units differ: BPC-157 + TB-500 Stack is dosed in varies by component, Vasoactive Intestinal Peptide (VIP) in mcg — they operate at different scales.
- Frequency: BPC-157 + TB-500 Stack is typically 2–3x per week; Vasoactive Intestinal Peptide (VIP) is Daily intranasal or 1–2x weekly subcutaneous.
How each works
BPC-157 + TB-500 Stack
BPC-157 and TB-500 work through entirely non-overlapping mechanisms and have been combined in numerous community protocols for injury recovery. BPC-157 drives angiogenesis and growth factor receptor expression; TB-500 regulates actin polymerization and cell migration into the injury site. No documented negative interactions exist — the combination is considered synergistic in the healing research community based on the complementary biology of each compound.
Vasoactive Intestinal Peptide (VIP)
VIP activates VPAC1 and VPAC2 receptors coupled to cAMP, suppressing pro-inflammatory cytokines while promoting Th2 regulatory immune responses and Treg differentiation. In the CIRS/biotoxin illness framework pioneered by Shoemaker, VIP intranasal formulation demonstrates normalization of inflammatory markers and improvement in TGF-β, MSH, and VIP deficiency seen in CIRS patients. Pulmonary vasodilation effects have been studied for PAH.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.